MVA:s CEO: “Our investments should improve people´s everyday lives”

Involuntary infertility and diabetes are two of the areas on the agenda of the Medicon Valley Alliance.

Astra Zeneca fick Swecares exportpris – ”Fenomenalt stark utveckling”

Ett globalt storbolag och en uppstickare delar på Swecare Export Awards 2024. Årets vinnare: läkemedelsjätten Astra Zeneca och sårvårdsbolaget PU sensor.

Stockholm aims at becoming one of the world’s top life science regions

Regional Chair for Finance, Irene Svenonius (M), believes that Stockholm can realise the goal of becoming one of the world’s top 5 regions in life science by 2025. One step on the way to achieve this is by hosting a world-leading congress in medtech....

Precision and accuracy in liquid handling

How to evaluate and optimize liquid handling performance

Anna Törner: Success requires bold decisions!

“Doing things right is fine, but doing the right things as soon as possible is even better”, writes Anna Törner in a column.

Acquisition of consulting company Key2Compliance

The Swedish company Key2Compliance, offering services in fields such as pharma and Medtech, has been acquired by German GBA Group.

The most important Swedish medical innovations: Our ranking

Life Science Sweden turns 20 years old – and celebrates by producing a top list of the 20 most important contemporary Swedish innovations in the field of medicine.

"Are we doing business the wrong way around in the Life Science Sector?"

For the past 50 years we have created solutions for problems that we thought would solve the problems. Pharmaceuticals have created big block buster drugs which...

Sweden and Denmark – this is how they choose their strategies

Scandinavia’s two major powers in pharmaceutical research have developed strategies for growth in life science, and both countries aim to become world leaders.

Zelmic

Affibody AB

Så mycket väntas lecanemab sälja globalt

Försäljningen av Leqembi (lecanemab), som nyligen fick ett accelererat USA-godkännande som behandling mot Alzheimers sjukdom, väntas globalt uppgå till sju milj...

Ny ordförande för Atlas Antibodies

Åsa Riisberg, styrelseproffs och tidigare partner i EQT, tar över ordförandeklubban i Atlas Antibodies.

Webinar: Medtech quality and regulatory compliance

This webinar is for you who are developing or planning to develop a medical device, combination, or borderline product. In one hour, we will discuss what you ne...

New Horizons in Biologics & Bioprocessing incl. Advanced Therapies: Stockholm (2026)

Marie Gårdmark: Big data evidence generation drives change in the EU regulatory system

Rapid developments in technology have led to the possibility for the generation and analysis of vast volumes of data. Will the availability of big data lead to ...

Pharma Outsourcing igång på Stockholm Waterfront

Är ditt ERP tillräckligt skalbart för att hantera Life Science?

Ett flexibelt och skalbart affärssystem är viktigt inom alla branscher men extra viktigt inom Life Science, varför då?

Norway finds its path in life science

The life science sector in Norway is on the rise.

Column: Why there cannot be a complete cure for cancer – but there is certainly another way!

"Is there a new way we need to be thinking about how to prevent cancer?" Lucy Robertshaw reflects upon which is the smartest way to beat cancer.

Svensk vaccinutvecklare får 24 miljoner av brittiskt forskningsprogram

Abera Bioscience får upp till motsvarande cirka 24 miljoner kronor i finansiering från ett brittiskt program inriktat på vacciner som ska stoppa epidemier i låg...

Nyckel till dödlig fästingburen sjukdom hittad av KI-forskare

Det extremt farliga Krim-Kongo blödarfebervirusets väg in i våra celler har identifierats av forskare vid Karolinska institutet – vilket kan bana väg för det fö...

Samtycke från patient – i många fall inte tillräckligt för databehandling

Vilka är konsekvenserna av att den Europeiska dataskyddsstyrelsen uttalat att försökspersoner i de flesta fall inte kan samtycka till hantering av data rörande ...

Column: Repurposing as a golden ticket to approval

"Hopefully, in the end, patients will be winners by receiving on-label treatments for which benefit-risk has been properly assessed." In a column Marie Gårdmark...